To assess refractive and astigmatic outcomes after PRK in eyes with moderate or high preoperative astigmatism and identify factors associated with residual astigmatism.
Approach:
Study design and participants: Retrospective, single-center evaluation of 112 eyes from 71 patients treated with PRK between May 2018 and March 2019: 69 eyes had moderate astigmatism (3.00–3.99 D) and 43 had high astigmatism (≥4.00 D).
Treatment and assessment: All eyes received non–wavefront-guided, aberration-free excimer laser ablation planned from manifest refraction. Visual acuity, refraction, safety and efficacy indices, and astigmatic vector outcomes were assessed through 12 months.
Key Findings:
Mean cylinder decreased from −3.76 D before surgery to −0.40 D at 12 months. At final follow-up, 76% of eyes were within 0.50 D and 96% within 1.00 D of the intended spherical equivalent target.
At 12 months, residual cylinder was ≤0.50 D in 64% of moderate-astigmatism eyes versus 28% of high-astigmatism eyes; residual cylinder >1.00 D occurred in 7% versus 30%, respectively.
The mean difference vector was 0.59 D in the moderate group and 0.97 D in the high group. Overall correction index was 1.07, indicating a slight tendency toward overcorrection in astigmatic magnitude.
UDVA better than 20/40 was achieved in 97% of eyes; mean efficacy and safety indices were 0.92 and 0.99. Angular accuracy was within 5 degrees in 71% and within 15 degrees in all eyes.
Higher preoperative cylinder and poorer preoperative corrected distance visual acuity were independently associated with greater residual astigmatism. Preoperative spherical refractive error was not independently associated.
Interpretation:
The study authors reported favorable overall visual and refractive outcomes, while eyes with higher baseline astigmatism had less precise cylinder correction. Longer mitomycin C application was associated with greater residual astigmatism, but the authors cautioned that this likely reflected confounding by indication.
Limitations:
Retrospective, single-center design, relatively small sample, and no control group.
Forty-one patients contributed both eyes, and follow-up was limited to 12 months, restricting assessment of long-term refractive stability.
The observational design and treatment-dependent mitomycin C exposure do not support causal conclusions about associated factors.
This week's research makes one thing clear: who someone is before they get sick — their relationships, their partner's health, the back of their eye — is doing a lot of work medicine is only beginning to account for.